The latest price target for MoonLake (NASDAQ:MLTX) was reported by Goldman Sachs on January 17, 2025. The analyst firm set a price target for $82.00 expecting MLTX to rise to within 12 months (a possible 82.06% upside). 31 analyst firms have reported ratings in the last year.

The latest analyst rating for MoonLake (NASDAQ:MLTX) was provided by Goldman Sachs, and MoonLake upgraded their buy rating.

The last upgrade for MoonLake Immunotherapeutics happened on January 17, 2025 when Goldman Sachs raised their price target to $82. Goldman Sachs previously had a neutral for MoonLake Immunotherapeutics.

The last downgrade for MoonLake Immunotherapeutics happened on August 26, 2024 when Wolfe Research changed their price target from N/A to N/A for MoonLake Immunotherapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of MoonLake, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for MoonLake was filed on January 17, 2025 so you should expect the next rating to be made available sometime around January 17, 2026.

While ratings are subjective and will change, the latest MoonLake (MLTX) rating was a upgraded with a price target of $62.00 to $82.00. The current price MoonLake (MLTX) is trading at is $45.04, which is out of the analyst’s predicted range.